BeOne Medicines
ONC · Nasdaq · Switzerland
Share price · ONC
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ONC's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 4 Nov 2026+6.4%
- 15 Oct 2026+6.4%
- 6 Jul 2026+4.0%
Nothing announced by ONC that day or the session before.
- 28 May 2026-3.1%
- 26 Feb 2026-8.5%
- 25 Feb 2026-4.5%
Nothing announced by ONC that day or the session before.
- 28 Jan 2026+4.1%
Nothing announced by ONC that day or the session before.
- 13 Jan 2026+5.1%
- 9 Jan 2026+5.5%
Nothing announced by ONC that day or the session before.
Share of unusual movement by asset
For each asset, the share of ONC's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(10 total)
| Target & Modality | |||
|---|---|---|---|
BAT1706(Avzivi) | Approved | VEGF-AMonoclonal antibody | Non-Small Cell Lung CancerOvarian CancerCervical CancerColorectal CancerRenal Cell CarcinomaGlioblastoma |
Daraxonrasib(Rasonque) | Approved | pan-RAS · RAS (pan-RAS, RAS-mutant tumors)Small molecule | Non-Small Cell Lung CancerPancreatic Ductal Adenocarcinoma |
Sonrotoclax(Beqalzi) | Approved | BCL-2Small molecule | Acute Myeloid LeukemiaMantle Cell LymphomaChronic Lymphocytic Leukemia |
| Approved | PD-1Monoclonal antibody | Non-Small Cell Lung CancerSmall Cell Lung CancerGastric CancerNasopharyngeal CarcinomaEsophageal Cancer Esophageal Squamous Cell Carcinoma | |
| Approved | HER2Multispecific antibody | Non-Small Cell Lung CancerBiliary Tract CancerBreast CancerGastric Cancer HER2-Positive Breast Cancer | |
zanubrutinib(Brukinsa) | Approved | BTKSmall molecule | Follicular LymphomaMantle Cell LymphomaChronic Lymphocytic Leukemia |
| Phase 3 | CDK4Small molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Phase 3 | GPC3 (glypican-3) x 4-1BB (CD137)Multispecific antibody | Non-Small Cell Lung CancerHepatocellular Carcinoma | |
| Phase 1 | CDK2Small molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Phase 1 | BCL-2Small molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer |
Upcoming events
(33 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (4)
November 2026 (2)
December 2026 (2)
What to watch
What to watch
2027 (7)
March 2027 (1)
What to watch
May 2027 (1)
What to watch
June 2027 (1)
What to watch
October 2027 (2)
December 2027 (2)
What to watch
What to watch
2028 (11)
February 2028 (1)
What to watch
March 2028 (1)
April 2028 (2)
What to watch
What to watch
July 2028 (1)
What to watch
August 2028 (2)
What to watch
What to watch
September 2028 (1)
What to watch
December 2028 (3)
What to watch
What to watch
What to watch
2029 (7)
March 2029 (1)
What to watch
April 2029 (1)
May 2029 (2)
What to watch
What to watch
September 2029 (2)
November 2029 (1)
What to watch
2030 (1)
April 2030 (1)
What to watch
2031 (2)
February 2031 (1)
What to watch
December 2031 (1)
What to watch
2032 (1)
February 2032 (1)
What to watch
Regulatory and conference events
(14)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
The 12 most recent of 14 past events are shown.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $1.9B | $661M | $5.9B | —$509M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $1.7B | $612M | $5.3B | —$463M operating cash flow | report ↗ |
| 2026-Q1 | $1.5B | — | $4.8B | — | report ↗ |
| 2025-Q3 | $1.4B | $524M | $4.1B | —$403M operating cash flow | report ↗ |
| 2025-Q2 | $1.3B | $525M | $2.8B | —$264M operating cash flow | report ↗ |
| 2025-Q1 | $1.1B | $482M | $2.5B | —$44M operating cash flow | report ↗ |
| 2024-Q3 | $1.0B | $496M | $2.7B | $121M$188M operating cash flow | report ↗ |
| 2024-Q2 | $929M | $454M | $2.6B | $120M-$96M operating cash flow | report ↗ |
| 2024-Q1 | $752M | $461M | $2.8B+ $0 short-term inv. | $251M-$309M operating cash flow | report ↗ |
| 2023-Q3 | $781M | $453M | $3.1B+ $107M short-term inv. | —-$78M operating cash flow | report ↗ |
| 2023-Q2 | $595M | $423M | $3.4B+ $106M short-term inv. | $381M-$294M operating cash flow | report ↗ |
| 2023-Q1 | $448M | $409M | $3.5B+ $294M short-term inv. | $348M-$564M operating cash flow | report ↗ |
| 2022-Q3 | $388M | $426M | $4.2B+ $872M short-term inv. | $558M-$562M operating cash flow | report ↗ |
| 2022-Q2 | $342M | $378M | $4.5B+ $1.2B short-term inv. | $571M-$380M operating cash flow | report ↗ |
| 2022-Q1 | $307M | $390M | $4.4B+ $1.9B short-term inv. | $434M-$237M operating cash flow | report ↗ |
| 2021-Q3 | $206M | $352M | $1.4B+ $2.5B short-term inv. | $414M-$496M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $5.3B | $2.1B | $4.6B | —$1.1B operating cash flow | report ↗ |
BeOne Medicines reported full-year 2025 revenue of $5,343.03M, up 40.2% YoY, with R&D spend of $2,145.87M, up 9.9% YoY. Cash and equivalents stood at $4,609.65M at year-end, and the company reported full-year GAAP net income of $286.9M.
For full-year 2026, the company guided total revenue to $6.2 billion to $6.4 billion. Key developments included first global approvals for sonrotoclax in China in relapsed/refractory mantle cell lymphoma and CLL/SLL, FDA priority review for sonrotoclax in R/R MCL, long-term BRUKINSA data from the SEQUOIA and ALPINE trials presented at ASH, and positive HERIZON-GEA-01 survival results for TEVIMBRA in HER2-positive gastroesophageal adenocarcinoma.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $3.8B | $2.0B | $2.6B | $161M-$141M operating cash flow | report ↗ |
| 2023-FY | $2.5B | $1.8B | $3.2B+ $2.6M short-term inv. | $220M-$1.2B operating cash flow | report ↗ |
| 2022-FY | $1.4B | $1.6B | $3.9B+ $665M short-term inv. | $501M-$1.5B operating cash flow | report ↗ |
| 2021-FY | $1.2B | $1.5B | $4.4B+ $2.2B short-term inv. | $353M-$1.3B operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 204 sales ($384.7M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-09 | Wang Xiaodong · director | Gift | 1,183 | — | — | Form 4 |
| 2026-11-06 | Ball Titus B. · Principal Accounting Officer | Option exercise | 880 | $207.55 | $183K | Form 4 |
| 2026-11-06 | Ball Titus B. · Principal Accounting Officer | Option exercise | 679 | $159.03 | $108K | Form 4 |
| 2026-11-06 | Ball Titus B. · Principal Accounting Officer | Open-market sale | 1,533 | $405.55 | $622K | Form 4 |
| 2026-11-06 | Ball Titus B. · Principal Accounting Officer | Open-market sale | 26 | $406.34 | $11K | Form 4 |
| 2026-11-06 | Ball Titus B. · Principal Accounting Officer | Option exercise (derivative) | 11,440 | — | — | Form 4 |
| 2026-11-06 | Ball Titus B. · Principal Accounting Officer | Option exercise (derivative) | 8,827 | — | — | Form 4 |
| 2026-11-05 | Lee Chan Henry · SVP, General Counsel | Open-market sale | 660 | $400.00 | $264K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 279 reporting institutions held 34.8M shares ($10.2B, 31.3% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BAKER BROS. ADVISORS LP | 8,799,053 | $2.6B |
| 2 | PRIMECAP MANAGEMENT CO/CA/ | 4,975,181 | $1.5B |
| 3 | Capital International Investors | 4,158,726 | $1.2B |
| 4 | FMR LLC | 3,693,610 | $1.1B |
| 5 | Capital World Investors | 1,622,687 | $481.9M |
| 6 | HHLR ADVISORS, LTD. | 1,034,306 | $307.2M |
| 7 | CITADEL ADVISORS LLC | 1,032,298 | $306.6M |
| 8 | Temasek Holdings (Private) Ltd | 862,643 | $256.2M |
| 9 | BlackRock, Inc. | 657,501 | $195.3M |
| 10 | Siren, L.L.C. | 465,000 | $138.1M |
| 11 | MORGAN STANLEY | 464,472 | $137.9M |
| 12 | UBS Group AG | 415,330 | $123.3M |
| 13 | BANK OF AMERICA CORP /DE/ | 405,273 | $120.4M |
| 14 | Baird Financial Group, Inc. | 349,651 | $103.8M |
| 15 | Capital International, Inc./CA/ | 302,243 | $89.8M |